Posted on June 13, 2016 by Sitemaster
Another important set of data that came out of the ASCO session that your sitemaster was unable to attend were the data presented by Dr. Maha Hussain on the use of the PARP inhibitor veliparib. …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, mCRPC, metastatic, PARP, veliparib | 2 Comments »
Posted on June 19, 2013 by Sitemaster
A Phase II clinical trial being coordinated by researchers at the University of Michigan Cancer Center is (as far as we know) the first trial ever to explore the potential of treatment for men with metastatic, castration-resistant prostate cancer (mCRPC) who carry the TMPRSS2-EPG fusion gene (as opposed to those who do not). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ABT-888, fusion, gene, inhibitor, PARP, TMPSS2-ERG, veliparib | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 